NU51PS005168
Cooperative Agreement
Overview
Grant Description
Integrated Viral Hepatitis Surveillance and Prevention - The purpose of this funding is to support viral hepatitis surveillance and prevention activities in Oregon. Key outcomes include:
1. Develop viral hepatitis outbreak protocols.
2. Improve surveillance for acute hepatitis A, B, and C, chronic hepatitis B and C, and perinatal HCV.
3. Utilize surveillance, cancer registry, hospitalization, vital records, and all payer all claims data to monitor the burden of disease of chronic viral hepatitis and the continuum of care for chronic HBV and HCV.
Convene a taskforce to develop a viral hepatitis elimination plan for Oregon.
Increase rates of HBV and HCV testing and linkage to care in settings such as syringe service programs (SSPs), substance use disorder (SUD) treatment centers, and emergency departments.
Improve access to harm reduction services preventing viral hepatitis and other infections among persons who inject drugs (PWID) and support improved access to prevention, diagnosis, and treatment of viral, bacterial, and fungal infections related to drug use.
Increase the number of primary healthcare providers trained to treat hepatitis B and C.
1. Develop viral hepatitis outbreak protocols.
2. Improve surveillance for acute hepatitis A, B, and C, chronic hepatitis B and C, and perinatal HCV.
3. Utilize surveillance, cancer registry, hospitalization, vital records, and all payer all claims data to monitor the burden of disease of chronic viral hepatitis and the continuum of care for chronic HBV and HCV.
Convene a taskforce to develop a viral hepatitis elimination plan for Oregon.
Increase rates of HBV and HCV testing and linkage to care in settings such as syringe service programs (SSPs), substance use disorder (SUD) treatment centers, and emergency departments.
Improve access to harm reduction services preventing viral hepatitis and other infections among persons who inject drugs (PWID) and support improved access to prevention, diagnosis, and treatment of viral, bacterial, and fungal infections related to drug use.
Increase the number of primary healthcare providers trained to treat hepatitis B and C.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Funding Agency
Place of Performance
Oregon
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 409% from $589,351 to $3,001,023.
Oregon Department Of Human Services was awarded
Oregon Viral Hepatitis Surveillance & Prevention Grant
Cooperative Agreement NU51PS005168
worth $3,001,023
from National Center for HIV, Viral Hepatitis, STD, and TB Prevention in May 2021 with work to be completed primarily in Oregon United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.270 Viral Hepatitis Prevention and Control.
The Cooperative Agreement was awarded through grant opportunity Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments.
Status
(Ongoing)
Last Modified 9/5/25
Period of Performance
5/1/21
Start Date
4/30/26
End Date
Funding Split
$3.0M
Federal Obligation
$0.0
Non-Federal Obligation
$3.0M
Total Obligated
Activity Timeline
Transaction History
Modifications to NU51PS005168
Additional Detail
Award ID FAIN
NU51PS005168
SAI Number
NU51PS005168-845455756
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
State Government
Awarding Office
75CDC1 CDC Office of Financial Resources
Funding Office
75CVJ0 CDC NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TUBERCULOSIS PREVENTION
Awardee UEI
HFJRBHKCBPR5
Awardee CAGE
1GVR0
Performance District
OR-90
Senators
Jeff Merkley
Ron Wyden
Ron Wyden
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Health and Human Services (075-0950) | Health care services | Grants, subsidies, and contributions (41.0) | $1,187,505 | 99% |
Modified: 9/5/25